Julia Serrano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Julia Serrano has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
- Rosa María López-Pintor
Department of Dental Clinical Specialties, ORALMED Research Group, School of Dentistry Complutense University Madrid Spain
5 shared publications - Elisabeth Casañas
Department of Dental Clinical Specialties, ORALMED research group, School of Dentistry, Complutense University, Madrid, Spain
3 shared publications - José González-Serrano
ORALMED Research group, Department of Dental Clinical Specialties Complutense University Madrid Spain
3 shared publications - Gonzalo Hernández
Department of Oral Medicine and Surgery, School of Dentistry, Complutense University, Madrid, Spain
2 shared publications EPOX‐SSp Group
1 shared publication- Fernando Hernández Ruiz de Azcárate
Department of Dental Clinical Specialities. ORALMED Research Group. School of Dentistry, Complutense University of Madrid, Plaza Ramón y Cajal s/n, 28040 Madrid, Spain
1 shared publication
Latest Publications
- 11 January 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (3) , 213-226.e3
Gingival hypersensitivity reactions to toothpastes
- 11 January 2024
- Published by Elsevier in The Journal of the American Dental Association
- Vol. 155 (3) , 213-226.e3
Gingival hypersensitivity reactions to toothpastes
- Open Access
- 30 September 2022
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 51 (9) , 810-817
Usefulness of implementing the OHIP‐14 questionnaire to assess the impact of xerostomia and hyposalivation on quality of life in patients with primary Sjögren's syndrome
Background: The aim of this study is to analyze if the results of the Oral Health Impact Profile‐14 questionnaire (OHIP‐14) in patients with primary Sjögren's syndrome (pSS) are correlated with salivary flow and level of xerostomia.Methods: This observational cross‐sectional study was conducted in 61 patients (60 women, one man, mean age 57.64 [13.52]) diagnosed of pSS according to the American‐European Criteria (2002). After recording demographic, medical and dental data (decayed‐missing‐filled teeth index [DMFT]), unstimulated (UWS) and stimulated (SWS) salivary flows were collected. Subsequently, UWS flow was categorized into two groups (r = 0.52; p = 0.001). Furthermore, there was a negative correlation between UWS and OHIP‐14 scores (r = −0.34; p = 0.006) and VAS for xerostomia (r = −0.22; p = 0.09). No significant correlation was found between SWS and OHIP‐14 or VAS neither between DMFT and OHIP‐14. When assessing the level of QoL by the UWS and SWS flow categories a significant association was found for UWS (p = 0.001) but not for SWS (p = 0.11). The OHIP‐14 values were higher in the groups with lower salivary flow. The multiple linear regression to predict OHIP‐14 only selected VAS for xerostomia as a statistically significant predictor.Conclusions: Increased level of xerostomia and reduced UWS flow decrease oral health‐related QoL in patients with pSS.
- 30 September 2022
- Published by Wiley in Journal of Oral Pathology & Medicine
- Vol. 51 (9) , 810-817
Open AccessUsefulness of implementing the OHIP‐14 questionnaire to assess the impact of xerostomia and hyposalivation on quality of life in patients with primary Sjögren's syndrome
Background: The aim of this study is to analyze if the results of the Oral Health Impact Profile‐14 questionnaire (OHIP‐14) in patients with primary Sjögren's syndrome (pSS) are correlated with salivary flow and level of xerostomia.Methods: This observational cross‐sectional study was conducted in 61 patients (60 women, one man, mean age 57.64 [13.52]) diagnosed of pSS according to the American‐European Criteria (2002). After recording demographic, medical and dental data (decayed‐missing‐filled teeth index [DMFT]), unstimulated (UWS) and stimulated (SWS) salivary flows were collected. Subsequently, UWS flow was categorized into two groups (r = 0.52; p = 0.001). Furthermore, there was a negative correlation between UWS and OHIP‐14 scores (r = −0.34; p = 0.006) and VAS for xerostomia (r = −0.22; p = 0.09). No significant correlation was found between SWS and OHIP‐14 or VAS neither between DMFT and OHIP‐14. When assessing the level of QoL by the UWS and SWS flow categories a significant association was found for UWS (p = 0.001) but not for SWS (p = 0.11). The OHIP‐14 values were higher in the groups with lower salivary flow. The multiple linear regression to predict OHIP‐14 only selected VAS for xerostomia as a statistically significant predictor.Conclusions: Increased level of xerostomia and reduced UWS flow decrease oral health‐related QoL in patients with pSS.
- Open Access
- 5 April 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (7) , 2478
Xerostomia and Salivary Flow in Patients Taking Antihypertensive Drugs
The aims of this systematic review are (1) to compare the prevalence of xerostomia and hyposalivation between patients taking antihypertensive drugs with a control group (CG), (2) to compare salivary flow rate between patients treated with a CG, and (3) to identify which antihypertensives produce xerostomia. This systematic review was carried out according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. To evaluate methodological quality of the eligible studies Cochrane Collaboration tool for assessing the risk of bias for clinical trials and the modified Newcastle–Ottawa scale case-control studies were used. The databases were searched for studies up to November 19th 2019. The search strategy yielded 6201 results and 13 publications were finally included (five clinical trials and eight case-control studies). The results of the included studies did not provide evidence to state that patients taking antihypertensives suffer more xerostomia or hyposalivation than patients not taking them. With regard to salivary flow, only two clinical studies showed a significant decrease in salivary flow and even one showed a significant increase after treatment. The case–control studies showed great variability in salivary flow, but in this case most studies showed how salivary flow is lower in patients medicated with antihypertensive drugs. The great variability of antihypertensive drugs included, the types of studies and the outcomes collected made it impossible to study which antihypertensive drug produces more salivary alterations. The quality assessment showed how each of the studies was of low methodological quality. Therefore, future studies about this topic are necessary to confirm whether antihypertensive drugs produce salivary alterations.
- 5 April 2020
- Published by MDPI AG in International Journal of Environmental Research and Public Health
- Vol. 17 (7) , 2478
Open AccessXerostomia and Salivary Flow in Patients Taking Antihypertensive Drugs
The aims of this systematic review are (1) to compare the prevalence of xerostomia and hyposalivation between patients taking antihypertensive drugs with a control group (CG), (2) to compare salivary flow rate between patients treated with a CG, and (3) to identify which antihypertensives produce xerostomia. This systematic review was carried out according to the preferred reporting items for systematic reviews and meta-analyses (PRISMA) guidelines. To evaluate methodological quality of the eligible studies Cochrane Collaboration tool for assessing the risk of bias for clinical trials and the modified Newcastle–Ottawa scale case-control studies were used. The databases were searched for studies up to November 19th 2019. The search strategy yielded 6201 results and 13 publications were finally included (five clinical trials and eight case-control studies). The results of the included studies did not provide evidence to state that patients taking antihypertensives suffer more xerostomia or hyposalivation than patients not taking them. With regard to salivary flow, only two clinical studies showed a significant decrease in salivary flow and even one showed a significant increase after treatment. The case–control studies showed great variability in salivary flow, but in this case most studies showed how salivary flow is lower in patients medicated with antihypertensive drugs. The great variability of antihypertensive drugs included, the types of studies and the outcomes collected made it impossible to study which antihypertensive drug produces more salivary alterations. The quality assessment showed how each of the studies was of low methodological quality. Therefore, future studies about this topic are necessary to confirm whether antihypertensive drugs produce salivary alterations.
- Open Access
- 25 October 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-11
Prevalence of Oral Mucosal Disorders in Diabetes Mellitus Patients Compared with a Control Group
Chronic hyperglycemia is associated with impaired wound healing and higher susceptibility to infections. It is unclear whether patients with diabetes mellitus (DM) present more oral mucosal disorders compared to control groups. The objectives were to compare (a) the prevalence rates of oral mucosal disorders in the DM and non-DM population and (b) the prevalence rates of specific disorders in the DM and non-DM population. Full-text articles were included if they met the following inclusion criteria: (a) they must be original articles from scientific journals, (b) they must be only cross-sectional studies in English, (c) the prevalence of oral mucosal disorders in DM patients must be evaluated, (d) results must be compared with a healthy control group, and (e) oral mucosal disorders must be specified in DM and non-DM group. All studies showed higher prevalence of oral mucosal disorders in DM patients in relation to non-DM population: 45–88% in type 2 DM patients compared to 38.3–45% in non-DM groups and 44.7% in type 1 DM patients compared to 25% in non-DM population. Tongue alterations and denture stomatitis were the most frequent significant disorders observed. The quality assessment following the Joanna Briggs Institute (JBI) Prevalence Critical Appraisal Tool showed the low quality of the existing studies.
- 25 October 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-11
Open AccessPrevalence of Oral Mucosal Disorders in Diabetes Mellitus Patients Compared with a Control Group
Chronic hyperglycemia is associated with impaired wound healing and higher susceptibility to infections. It is unclear whether patients with diabetes mellitus (DM) present more oral mucosal disorders compared to control groups. The objectives were to compare (a) the prevalence rates of oral mucosal disorders in the DM and non-DM population and (b) the prevalence rates of specific disorders in the DM and non-DM population. Full-text articles were included if they met the following inclusion criteria: (a) they must be original articles from scientific journals, (b) they must be only cross-sectional studies in English, (c) the prevalence of oral mucosal disorders in DM patients must be evaluated, (d) results must be compared with a healthy control group, and (e) oral mucosal disorders must be specified in DM and non-DM group. All studies showed higher prevalence of oral mucosal disorders in DM patients in relation to non-DM population: 45–88% in type 2 DM patients compared to 38.3–45% in non-DM groups and 44.7% in type 1 DM patients compared to 25% in non-DM population. Tongue alterations and denture stomatitis were the most frequent significant disorders observed. The quality assessment following the Joanna Briggs Institute (JBI) Prevalence Critical Appraisal Tool showed the low quality of the existing studies.
- Open Access
- 10 July 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-15
Xerostomia, Hyposalivation, and Salivary Flow in Diabetes Patients
The presence of xerostomia and hyposalivation is frequent among diabetes mellitus (DM) patients. It is not clear if the presence of xerostomia and hyposalivation is greater in DM than non-DM patients. The aims of this systematic review are (1) to compare the prevalence rates of xerostomia, (2) to evaluate the salivary flow rate, and (3) to compare the prevalence rates of hyposalivation in DM versus non-DM population. This systematic review was conducted according to the PRISMA group guidelines by performing systematic literature searches in biomedical databases from 1970 until January 18th, 2016. All studies showed higher prevalence of xerostomia in DM patients in relation to non-DM population, 12.5%–53.5% versus 0–30%. Studies that analyzed the quantity of saliva in DM population in relation to non-DM patients reported higher flow rates in non-DM than in DM patients. The variation flow rate among different studies in each group (DM/CG) is very large. Only one existing study showed higher hyposalivation prevalence in DM than non-DM patients (45% versus 2.5%). In addition, quality assessment showed the low quality of the existing studies. We recommend new studies that use more precise and current definitions concerning the determination and diagnosis of DM patients and salivary flow collection.
- 10 July 2016
- Published by Wiley in Journal of Diabetes Research
- Vol. 2016, 1-15
Open AccessXerostomia, Hyposalivation, and Salivary Flow in Diabetes Patients
The presence of xerostomia and hyposalivation is frequent among diabetes mellitus (DM) patients. It is not clear if the presence of xerostomia and hyposalivation is greater in DM than non-DM patients. The aims of this systematic review are (1) to compare the prevalence rates of xerostomia, (2) to evaluate the salivary flow rate, and (3) to compare the prevalence rates of hyposalivation in DM versus non-DM population. This systematic review was conducted according to the PRISMA group guidelines by performing systematic literature searches in biomedical databases from 1970 until January 18th, 2016. All studies showed higher prevalence of xerostomia in DM patients in relation to non-DM population, 12.5%–53.5% versus 0–30%. Studies that analyzed the quantity of saliva in DM population in relation to non-DM patients reported higher flow rates in non-DM than in DM patients. The variation flow rate among different studies in each group (DM/CG) is very large. Only one existing study showed higher hyposalivation prevalence in DM than non-DM patients (45% versus 2.5%). In addition, quality assessment showed the low quality of the existing studies. We recommend new studies that use more precise and current definitions concerning the determination and diagnosis of DM patients and salivary flow collection.